Simple Summary Oncolytic viruses (OVs) are viruses that selectively target and kill cancer
cells while sparing normal ones. OVs are from diverse families of viruses, but naturally …

Applications of viral vectors have found an encouraging new beginning in gene therapy in
recent years. Significant improvements in vector engineering, delivery, and safety have …

In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy.
Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self …

Malignant brain tumors constitute nearly one-third of cancer diagnoses in children and have
recently surpassed hematologic malignancies as the most lethal neoplasm in the pediatric …

Abstract In this White Paper, we discuss the current state of microbial cancer therapy. This
paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National …

Immunotherapy has recently garnered success with the induction of clinical responses in
tumors, which are traditionally associated with poor outcomes. Chimeric antigen receptor T …

In 2015, oncolytic virotherapy was approved for clinical use, and in 2017, recombinant
adeno-associated virus (AAV) delivery was also approved. However, systemic …

Biological therapies have changed the face of oncology by targeting cancerous cells while
reducing the effect on normal tissue. This publication focuses mainly on new therapies that …

Malignant tumors of the central nervous system (CNS) continue to be a leading cause of
cancer-related mortality in both children and adults. Traditional therapies for malignant brain …

Pediatric high-grade brain tumors and adult glioblastoma are associated with significant
morbidity and mortality. Oncolytic herpes simplex virus-1 (oHSV) is a promising approach to …